Redeye: AroCell - Funding secured, next step - FDA

Report this content

We adjust our financial projections given a new view on pricing and market uptake for AroCell. In our update we slightly raise our Base Case to SEK 2.5 per share and discuss the capital raise, which we believe will fund operations until FDA approval in 2021.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.